Home News Issues My AVMA Jobs Animal Health Public Health
Search Tips | Advanced Search
  
 
Search within Advocacy only.

Federal

Legislative activities



Regulatory activities

 

State

State legislative resources

 

Get involved

AVMA Member area About AVMAPAC



Government
Action Center



Congressional fellowships



Student externships

 

AVMA Member area = AVMA/SAVMA  Members Only


Get Adobe reader

Some files on this page require Adobe Reader software. Click on the image above to download it for free from the Adobe site.

 




 
Federal regulatory practice issues: Vaccines

Changing Bovine Viral Diarrhea Virus vaccine labels
Formal title:
USDA Center for Veterinary Biologics (CVB) Notice No. Draft-007: Type (Species) Designation of Vaccines Containing Bovine Viral Diarrhea Virus(es)

View document on USDA Web site (PDF, 34Kb)

Summary
The USDA Center for Veterinary Biologics proposes that Bovine Viral Diarrhea Virus (BVDV) vaccine labels include the vaccine BVDV type(s) in the indications statement and the type of the BVDV challenge virus for which efficacy has been demonstrated as part of the product claim.

In principle, the AVMA is very pleased with the CVB's attempt to provide additional science-based information on biologic labels to help veterinarians have a clearer expectation of product performance. However, we believe the diversity of BVDV and the accompanying variability in biologic protection poses significant challenges. As proposed, the CVB draft may cause more problems for veterinarians who recommend and/or administer vaccines than it may solve because it oversimplifies the dynamics of BVDV protection.

To resolve our concerns, the AVMA recommends that the vaccine virus type and challenge type be identified only if accompanied by a statement on the label of all BVDV products that explains that because of the diversity of BVDV, protection between and among virus types is variable.

Response
View AVMA response to USDA (PDF)
Conclusion

The USDA concluded that BVDV Type(s) included in a biologic should be disclosed on the label as part of the indications statement. In addition, the label should indicate, as part of the product claim, the Type of BVD challenge virus for which efficacy has been demonstrated.

View USDA conclusion (PDF, 25Kb)

 


American Veterinary Medical Association
Copyright © 2008